It was a great honor for Adam Milstein to be named among the top 200 most influential persons in the world of benevolence. He was ranked number 187 on the list. The base was the influence that both his Facebook and Twitter account has on benevolence. He was entirely humbled to have appeared on the same lists with business leaders such as Warren Buffett, Bill and Melinda Gates, Elon Musk as well as Mark Zuckerberg. On the lists also were politicians such as Hillary Clinton and Barack Obama. Also featuring on the list were renowned public figures such as Oprah Winfrey and J.K. Rowling.
He disclosed that among the parts of his life that give him absolute gratification is his philanthropic work. Seeing his name included on the list of the many leaders made him more humbled. He extended his appreciations to his dear wife Gila and to the IAC and the numerous organizations that he has partnered with in his journey of making a difference in life.
The idea of philanthropy got introduced to Adam Milstein by his longtime friend known as Modern Orthodox, who kept on reminding him of the importance of doing something worthwhile, that will bring about a difference rather than keeping on making more and more money.
In conjunction with his wife Gila, Adam Milstein established a family organization that sponsors young professionals and students who associate themselves with the Jewish origin. The Milstein Family Foundation blossoms in two pillars: strengthening the Jewish people and their homeland. Adam Milstein revealed on the intention of the family foundation to continue working with an eye on making stronger the Jewish people and the state of Israel, through strengthening the bond of organizations.
Adam Milstein co-founded a rapidly growing Jewish firm in America known as Israeli-American Council where he chairs its national expansion. In Jewish agencies such as StandWithUs, the Israel on Campus Coalition, Hasbara Fellowships and AIPAC, Adam Milstein is a leader.
Adam Milstein graduated from the Israeli Institute of Technology in 1974 with a Bachelor’s of Science in business and economics. In 1983, he got his MBA from University of Southern California, Los Angeles.
Clay Siegall is one of the most reputed scientists in the field of biotechnology and has helped make significant contributions in the field, especially in the area of cancer therapies. Clay Siegall serves as the Chairman of the board and the CEO of Seattle Genetics, which is one of the leading biotechnology firms in the United States and has acclaimed popularity across the globe.
Clay Siegall maintains a personal blog online that updates on the various events in the field of biotechnology. One of his recent updates involves talking about how scientists have discovered that part of the reason why cancer occurs in many people is due to bad luck. Clay Siegall, as the CEO of Seattle Genetics, has helped in increasing the turnover of the company over the years. His efforts helped Seattle Genetics to secure the approval of FDA in the year 2011 for the highly acclaimed ADC product named ADCETRIS, which is a globally used cancer therapy drug used in over 65 countries.
Clay Siegall helped Seattle Genetics raised over $330 million in funding from private and public financing sources during capital raising activities. Thanks to the leadership skills of Clay Siegall, the company has networked with many other leading pharmaceutical companies from around the world, including Genentech, CuraGen, Progenics, MedImmune, and Bayer. The collaboration with other groups has helped the company to enhance its revenue substantially and has helped the company add over $65 million in revenue since 2001.
Clay Siegall is highly qualified academically and has completed Bachelor in Science from Zoology from the University of Maryland and done Ph.D. from George Washington University. He has had an extensive career in the field of medicine and biotechnology, and before founding Seattle Genetics, he has worked with Bristol-Myers Squibb Pharmaceutical Research Institute and National Cancer Institute for many years. He was also with National Institutes of Health for 3 years between 1988 to 1991. He holds over 15 patents and has written many articles, book chapters and reviews that are published in over 70 publications till date. He is one of the most prominent figures in the field of biotechnology and continues to stay committed to developing highly efficient cancer therapies.